SESSION TITLE: Wednesday Abstract Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/23/2019 09:45 AM - 10:45 AM PURPOSE: Knowledge is limited regarding the differences between triple therapy (ICS/LABA/LAMA) and dual bronchodilator therapy for COPD practice. This study was conducted to determine whether online independent medical education could improve pulmonologists’ and primary care physicians’ (PCP) knowledge and confidence related to the impact of triple therapy and dual bronchodilators in the management of COPD. METHODS: Physicians participated in a 25-minute, 2-faculty, video-based, online CME activity with synchronized slides. The effects of education were assessed using a 3-question, repeated pairs, pre-assessment/post-assessment study design. For all questions combined, the chi-square test assessed differences from pre- to post-assessment. P values RESULTS: Overall significant improvements were seen after the education for both pulmonologists (average correct response rate of 74% at pre-assessment vs 86% at post-assessment; P • The impact of triple vs dual therapy on exacerbation rates - Based on the IMPACT trial: A 12% relative improvement among pulmonologists (80% vs 87%; P=.0338) and an 18% improvement for PCPs (73% vs 83%; P<.001) - Based on the TRIBUTE trial: A 19% relative improvement among pulmonologists (73% vs 85%; P<.001) • The recommendations for ICS use in COPD based on GOLD guidelines: An 18% relative improvement among pulmonologists (70% vs 84%; P<.001) A total of 9% of pulmonologists and 26% of PCPs improved their confidence related to prescribing a triple inhaled therapy for their patients with COPD. Ongoing educational gaps relate to patient selection and the optimal use of dual bronchodilator and triple therapy as new clinical data continue to emerge. CONCLUSIONS: This study demonstrates the success of online, 2-faculty, video-based education in improving the knowledge and confidence of pulmonologists and PCPs regarding the use of triple therapy versus dual bronchodilation in COPD. CLINICAL IMPLICATIONS: Properly implemented, this type of intervention can translate into improvements in patient care and long-term outcomes. DISCLOSURES: Speaker/Speaker's Bureau relationship with Medtronic Please note: $5001 - $20000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Boston Scientific Please note: $5001 - $20000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Biotronik Please note: $5001 - $20000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with livanova Please note: $5001 - $20000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with physiomed Please note: $1001 - $5000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with bayer Please note: $1001 - $5000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with BMS-Pfizer Please note: $1001 - $5000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Boehringer Ingelheim Please note: $1001 - $5000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Servier Please note: $5001 - $20000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with novartis Please note: $1-$1000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with MEDA Please note: $1-$1000 Added 03/15/2019 by Walid AMARA, source=Web Response, value=Honoraria no disclosure on file for Wilma Guerra; No relevant relationships by Trevor Lambert, source=Web Response no disclosure on file for Caroline Phillips; No relevant relationships by Christy Rohani-Montez, source=Web Response no disclosure on file for Dermot Ryan